Rational design and engineering of therapeutic proteins

Pharmafocus (2002) Biotechnology 2006: Shaping the Future. Available at: http://www.pharmafile.com/Pharmafocus/Features/feature.asp?fID=281 Voigt, 2002, Protein building blocks preserved by recombination, Nat. Struct. Biol., 9, 553 Voigt, 2001, Computationally focusing the directed evolution of proteins, J. Cell. Biochem. Suppl., 37, 58, 10.1002/jcb.10066 Lin, 1998, Betaseron, Dev. Biol. Stand., 96, 97 Arakawa, 1993, Cysteine 17 of recombinant human granulocyte colony stimulating factor is partially solvent-exposed, J. Protein Chem., 12, 525, 10.1007/BF01025117 Culajay, 2000, Thermodynamic characterization of mutants of human fibroblast growth factor 1 with an increased physiological half-life, Biochemistry, 39, 7153, 10.1021/bi9927742 Desjarlais, 1995, De novo design of the hydrophobic cores of proteins, Protein Sci., 4, 2006, 10.1002/pro.5560041006 Hellinga, 1994, Optimal sequence selection in proteins of known structure by simulated evolution, Proc. Natl. Acad. Sci. U. S. A., 91, 5803, 10.1073/pnas.91.13.5803 Hurley, 1992, Design and structural analysis of alternative hydrophobic core packing arrangements in bacteriophage T4 lysozyme, J. Mol. Biol., 244, 1143, 10.1016/0022-2836(92)90475-Y Dahiyat, 1997, Automated design of the surface positions of protein helices, Protein Sci., 6, 1333, 10.1002/pro.5560060622 Malakauskas, 1998, Design, structure, and stability of a hyperthermophilic protein variant, Nat. Struct. Biol., 5, 470, 10.1038/nsb0698-470 Marshall, 2002, Electrostatics significantly affect the stability of designed homeodomain variants, J. Mol. Biol., 316, 189, 10.1006/jmbi.2001.5326 Filikov, 2002, Computational stabilization of human growth hormone, Protein Sci., 11, 1452, 10.1110/ps.3500102 Luo, 2002, Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening, Protein Sci., 11, 1218, 10.1110/ps.4580102 Pipe, 1997, Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa, Proc. Natl. Acad. Sci. U. S. A., 94, 11851, 10.1073/pnas.94.22.11851 Agren, 1999, Hydrophobicity engineering of cholera toxin A1 subunit in the strong adjuvant fusion protein CTA1-DD, Protein Eng., 12, 173, 10.1093/protein/12.2.173 Tan, 1998, Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility, Immunotechnology, 4, 107, 10.1016/S1380-2933(98)00011-6 Sytkowski, 1999, An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties, J. Biol. Chem., 274, 24773, 10.1074/jbc.274.35.24773 Goldenberg, 1999, Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis, Clin. Ther., 21, 75, 10.1016/S0149-2918(00)88269-7 Syed, 1997, Potent antithrobmin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin, Blood, 89, 3243, 10.1182/blood.V89.9.3243 Marques, 2001, A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro, Thromb. Haemost., 86, 902, 10.1055/s-0037-1616148 Dennis, 2002, Albumin-binding as a general strategy of improving the pharmacokinetics of proteins, J. Biol. Chem., 277, 35035, 10.1074/jbc.M205854200 Vajo, 2000, Genetically engineered insulin analogs: diabetes in the new millenium, Pharmacol. Rev., 52, 1 Knauf, 1988, Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers, J. Biol. Chem., 263, 15064, 10.1016/S0021-9258(18)68146-3 Clark, 1996, Long-acting growth hormones produced by conjugation with polyethylene glycol, J. Biol. Chem., 271, 21969, 10.1074/jbc.271.36.21969 Harris, 2001, Pegylation: a novel process for modifying pharmacokinetics, Clin. Pharmacokinet., 40, 539, 10.2165/00003088-200140070-00005 Roberts, 2002, Chemistry for peptide and protein PEGylation, Adv. Drug Deliv. Rev., 54, 459, 10.1016/S0169-409X(02)00022-4 Kinstler, 2002, Mono-N-terminal poly(ethylene glycol)-protein conjugates, Adv. Drug Deliv. Rev., 54, 447, 10.1016/S0169-409X(02)00023-6 Bailon, 2001, Rational design of a potent, long-lasting form of interferon: a 40-kDa-branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C, Bioconjug. Chem., 12, 195, 10.1021/bc000082g Wang, 2002, Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications, Adv. Drug Deliv. Rev., 54, 547, 10.1016/S0169-409X(02)00027-3 MacDougall, 1999, Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients, J. Am. Soc. Nephrol., 10, 2392, 10.1681/ASN.V10112392 French, 1995, Intracellular traffiking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction, J. Biol. Chem., 270, 4334, 10.1074/jbc.270.9.4334 Sarkar, 2002, Rational cytokine design for increased lifetime and enhanced potency using pH activated histidine-switching, Nat. Biotechnol., 20, 908, 10.1038/nbt725 Weintraub, 1999, Development and in vitro characterization of human recombinant thyrotropin, Thyroid, 9, 447, 10.1089/thy.1999.9.447 Grossmann, 1998, A rational design strategy for protein hormone superagonists, Nat. Biotechnol., 16, 871, 10.1038/nbt0998-871 Siemeister, 1998, An antagonistic vascular endothelial grown factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells, Proc. Natl. Acad. Sci. U. S. A., 95, 4625, 10.1073/pnas.95.8.4625 Savino, 1994, Rational design of a receptor super-antagonist of human interleukin-6, EMBO J., 13, 5863, 10.1002/j.1460-2075.1994.tb06931.x Fuh, 1992, Rational design of potent antagonists to the human growth hormone receptor, Science, 256, 1677, 10.1126/science.256.5064.1677 Olson, K. et al. (1998) Human Growth Hormone Variants. US patent number 5849535. Lu, 2001, An isolated, surface expressed I domain of the integrin alphaL beta2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond, Proc. Natl. Acad. Sci. U. S. A., 98, 2387, 10.1073/pnas.041606398 Shimaoka, 2001, Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin alphaL I domains with high affinity and antagonist activity in vivo, Proc. Natl. Acad. Sci. U. S. A., 98, 6009, 10.1073/pnas.101130498 Shimaoka, 2000, Computational design of an integrin I domain stabilized in the open high affinity conformation, Nat. Struct. Biol., 7, 674, 10.1038/77978 Antonelli, 1999, Development of antibodies to interferon beta in patients: technical and biological aspects, Eur. Cytokine Netw., 10, 413 He, 1999, Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation, Life Sci., 65, 355, 10.1016/S0024-3205(99)00257-X Meyer, 2001, Reduced antibody response to streptavidin through site-directed mutagenesis, Protein Sci., 10, 491, 10.1110/ps.19901 Laroche, 2000, Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes, Blood, 96, 1425, 10.1182/blood.V96.4.1425 Worn, 2001, Stability engineering of antibody single chain Fv fragments, J. Mol. Biol., 305, 989, 10.1006/jmbi.2000.4265 Tamura, 2000, Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only, J. Immunol., 164, 1432, 10.4049/jimmunol.164.3.1432 Chen, 1999, Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen, J. Mol. Biol., 293, 865, 10.1006/jmbi.1999.3192 Rader, 1998, A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries, Proc. Natl. Acad. Sci. U. S. A., 95, 8910, 10.1073/pnas.95.15.8910 Baca, 1997, Antibody humanization using monovalent phage display, J. Biol. Chem., 272, 10678, 10.1074/jbc.272.16.10678 Griffiths, 1998, Strategies for selection of antibodies by phage display, Curr. Opin. Biotechnol., 9, 102, 10.1016/S0958-1669(98)80092-X Maynard, 2000, Antibody engineering, Annu. Rev. Biomed. Eng., 2, 339, 10.1146/annurev.bioeng.2.1.339 Pluckthun, 1997, New protein engineering approaches to multivalent and bispecific antibody fragments, Immunotechnology, 3, 83, 10.1016/S1380-2933(97)00067-5 Ravetch, 2001, IgG Fc receptors, Annu. Rev. Immunol., 19, 275, 10.1146/annurev.immunol.19.1.275 Raghavan, 1996, Fc receptors and their interactions with immunoglobulins, Annu. Rev. Cell Dev. Biol., 12, 181, 10.1146/annurev.cellbio.12.1.181 Shields, 2001, High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R, J. Biol. Chem., 276, 6591, 10.1074/jbc.M009483200 Shields, 2002, Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity, J. Biol. Chem., 277, 26733, 10.1074/jbc.M202069200 Umana, 1999, Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity, Nat. Biotechnol., 17, 176, 10.1038/6179 Ghetie, 1997, Increasing the serum persistence of an IgG fragment by random mutagenesis, Nat. Biotechnol., 15, 637, 10.1038/nbt0797-637 Kim, 1999, Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn, Eur. J. Immunol., 29, 2819, 10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6 Street, 1999, Computational protein design, Structure Fold Des., 7, R105, 10.1016/S0969-2126(99)80062-8 Mendes, 2002, Energy estimation in protein design, Curr. Opin. Struct. Biol., 12, 441, 10.1016/S0959-440X(02)00345-7 Pokala, 2001, Review: Protein design- Where we were, where we are, where we're going, J. Struct. Biol., 134, 269, 10.1006/jsbi.2001.4349 Kraemer-Pecore, 2001, Computational protein design, Curr. Opin. Chem. Biol., 5, 690, 10.1016/S1367-5931(01)00267-8 Dahiyat, 1996, Protein design automation, Protein Sci., 5, 895, 10.1002/pro.5560050511 Dahiyat, 1997, De novo protein design: fully automated sequence selection, Science, 278, 82, 10.1126/science.278.5335.82